Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lilly's Portrazza: Box Warning + Modest Efficacy Could Still = Sales Success

Executive Summary

EGFR inhibitor necitumumab may find place in first-line squamous type non-small cell lung cancer market due to limited treatment options – at least for now.

Advertisement

Related Content

Lilly's Necitumumab: FDA Panel To Weigh Modest Survival Benefit Against Thromboembolic Risks

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register